E

$PBYI – plain sailing or death by a thousand cuts?

A look at the FDA briefing docs on Puma's neratinib

May 23, 2017
E

On Kite’s cerebral edema and Genentech’s IMvigor211 miss

We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?

May 10, 2017
E

BSB Mailbag on ROS1, ALK and TRK inhibitors

BSB Reader Mailbag on TRK/ROS1/ALK inhibitors

April 28, 2017
E

Asking Good Questions is both an Art and a Science

Latest BSB reader Q&A looks at 5 questions from subscribers

March 16, 2017
E

On APHINITY, SOLO2 and Immunomedics

Reader Q&A on women's cancers relating to HER2, PARP and TNBC...

February 13, 2017
E

Can we expect more surprises in 1L NSCLC?

A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape

January 18, 2017
E

September BSB Reader Mailbag

Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16

September 29, 2016
E

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016
E

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015
E

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015
E

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015